At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,484 enrolled
Drug / intervention
Anastrozoledrug
Likely dose
Anastrozole 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy
In Brief
A Phase 3 clinical trial evaluating Anastrozole for Breast Cancer. Completed, enrolled 3,484 participants across 60 sites.
Detailed Summary
The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesAustria
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2004
First PostedFeb 2006
Primary CompletionJun 2017
TodayJul 2026
First PostedFeb 24, 2006
Enrollment StartMar 1, 2004
Primary CompletionJun 30, 2017
TodayJul 2, 2026
Enrollment to primary: 13.3 yearsPosted 20.4 years ago
Interventions
Anastrozoledrug
1mg tablet daily